Skip to main content

Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supply

Demand for the drugs Mounjaro and Zepbound has far outpaced supply over the last year, forcing Eli Lilly to invest heavily to scale up its manufacturing.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.